MERSANA THERAPEUTICS INC (MRSN)
US59045L1061 - Common Stock
MERSANA THERAPEUTICS INC
NASDAQ:MRSN (1/10/2025, 4:36:52 PM)
After market: 0.73 +0.01 (+1.39%)0.72
-0.58 (-44.62%)
Company Profile
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 123 full-time employees. The company went IPO on 2017-06-28. The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The firm's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
Company Info
MERSANA THERAPEUTICS INC
840 Memorial Dr
Cambridge MASSACHUSETTS 02139
P: 16174980020
CEO: Anna Protopapas
Employees: 123
Website: https://www.mersana.com/
MRSN News
4 hours ago - Yahoo FinanceWhy Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events reported. At intermediate doses in the trial (38.1 mg/m2 to 67.4 mg/m2), the confirmed objective response rate among evaluable patients was 23% (6 of 26 patients) across all B7-H4 high tumors and 23% (3 of 13 patients) with B7-H4 high TNBC, all of whom had
8 hours ago - ChartmillWondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.Get insights into the top gainers and losers of Friday's pre-market session.
11 hours ago - Mersana Therapeutics, Inc.Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET...
11 hours ago - Mersana Therapeutics, Inc.Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile- Promising clinical activity observed in...
a month ago - Market News VideoNotable Wednesday Option Activity: ITT, DUOL, MRSN2 months ago - Mersana Therapeutics, Inc.Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsPlan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056...
MRSN Twits
Here you can normally see the latest stock twits on MRSN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
